DMAT, an inhibitor of protein kinase CK2 induces reactive oxygen species and DNA double strand breaks. 2009

Carolin C Schneider, and Andrea Hessenauer, and Claudia Götz, and Mathias Montenarh
Medizinische Biochemie und Molekularbiologie, Universität des Saarlandes, 66424 Homburg, Germany.

Elevated levels of protein kinase CK2 were found in tumour cells compared to normal cells. Thus, inhibition of CK2 kinase activity seems to be an attractive method to stop growth of cancer cells. Two drugs, namely tetrabromobenzotriazole, TBB, and 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole, DMAT were found to specifically inhibit CK2 and to induce apoptosis in tumour cells. The aim of the present study was the elucidation of the mode of action of these two inhibitors in addition to the inhibition of CK2 activity. The decrease in CK2 kinase activity induced by both inhibitors was accompanied by a reduction in cell viability and induction of apoptosis. Most interestingly, we detected that DMAT in contrast to TBB induced reactive oxygen species, ROS and DNA-double-strand-breaks (DSBs). Thus, in addition to inhibition of CK2 one has to consider ROS and DSBs contributing to the induction of apoptosis by DMAT.

UI MeSH Term Description Entries
D008297 Male Males
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001562 Benzimidazoles Compounds with a BENZENE fused to IMIDAZOLES.
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D014230 Triazoles Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3. Triazole
D015854 Up-Regulation A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Up-Regulation,Upregulation,Up-Regulation (Physiology),Up Regulation
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis

Related Publications

Carolin C Schneider, and Andrea Hessenauer, and Claudia Götz, and Mathias Montenarh
December 2004, Blood,
Carolin C Schneider, and Andrea Hessenauer, and Claudia Götz, and Mathias Montenarh
April 2004, Cell,
Carolin C Schneider, and Andrea Hessenauer, and Claudia Götz, and Mathias Montenarh
March 2020, Journal of radiation research,
Carolin C Schneider, and Andrea Hessenauer, and Claudia Götz, and Mathias Montenarh
March 2002, Mutation research,
Carolin C Schneider, and Andrea Hessenauer, and Claudia Götz, and Mathias Montenarh
January 1994, Methods in enzymology,
Carolin C Schneider, and Andrea Hessenauer, and Claudia Götz, and Mathias Montenarh
September 2020, Parasites & vectors,
Carolin C Schneider, and Andrea Hessenauer, and Claudia Götz, and Mathias Montenarh
December 2009, Cancer research,
Carolin C Schneider, and Andrea Hessenauer, and Claudia Götz, and Mathias Montenarh
January 2006, Cancer research,
Carolin C Schneider, and Andrea Hessenauer, and Claudia Götz, and Mathias Montenarh
October 1996, Japanese journal of cancer research : Gann,
Carolin C Schneider, and Andrea Hessenauer, and Claudia Götz, and Mathias Montenarh
October 2008, Cancer letters,
Copied contents to your clipboard!